• If you are wondering whether Globus Medical's current share price offers fair value or not, the recent trading pattern gives you plenty to think about.
• The stock closed at US$83.51, with returns of a 4.2% decline over the last 7 days and a 12.5% decline over 30 days, while still sitting on a 14.1% gain over 1 year, 46.7% over 3 years and 33.0% over 5 years.
• Recent news coverage has focused on Globus Medical's position in the medical devices space and how its product portfolio fits into long term trends in healthcare procedures and technologies. This backdrop helps frame why the share price has seen short term pressure even as longer term returns remain positive.
• Globus Medical currently has a valuation score of 5/6. The next sections will break down how different valuation methods arrive at this, before finishing with a way to think about value that goes beyond the usual ratios.

Approach 1: Globus Medical Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model starts with estimates of the cash a company could generate in the future, then discounts those projected cash flows back to today to arrive at an estimate of what the business might be worth right now.

For Globus Medical, the latest twelve month Free Cash Flow (FCF) is reported at $603.6 million. Analysts provide specific FCF estimates out to 2027, with Simply Wall St extrapolating further. The model includes a ten year path that runs from an estimated $395.6 million in 2026 to $663.9 million in 2035, all in dollar terms and all based on a 2 Stage Free Cash Flow to Equity approach.

When those projected cash flows are discounted back, the DCF model arrives at an estimated intrinsic value of US$84.55 per share. Against the recent share price of US$83.51, this implies the stock is about 1.2% undervalued, which is a very small gap and suggests the market price and model estimate are broadly aligned.

Result: ABOUT RIGHT

Globus Medical is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Globus Medical Price vs Earnings

For a profitable company like Globus Medical, the P/E ratio is a straightforward way to relate what you pay per share to the earnings that support that price. Investors usually accept a higher P/E when they expect stronger growth or see lower risk, while slower growth or higher risk tends to justify a lower, more conservative P/E as a normal range.

Globus Medical currently trades on a P/E of 21.0x. That sits below the Medical Equipment industry average P/E of 27.3x and also below the peer group average of 50.2x. Simply Wall St goes a step further by estimating a Fair Ratio of 22.4x, which is the P/E that might be expected given factors such as Globus Medical’s earnings profile, profit margins, industry, market cap and risk characteristics.

This Fair Ratio is more tailored than a simple comparison with peers or the sector because it adjusts for company specific attributes instead of assuming all Medical Equipment stocks deserve the same multiple. With the current P/E at 21.0x versus a Fair Ratio of 22.4x, the shares appear undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Globus Medical Narrative

Earlier it was mentioned that there is an even better way to think about valuation. This is where Narratives come in, giving you a simple story behind the numbers by linking your view of Globus Medical’s future revenue, earnings and margins to a financial forecast and then to a Fair Value that can be compared with the current price.

On Simply Wall St’s Community page, Narratives are an easy tool used by millions of investors to set out a clear thesis. They update automatically when new information, such as earnings or news on acquisitions like NuVasive and Nevro, feeds into the underlying assumptions.

For Globus Medical, one investor might align with a more bullish Narrative that uses a Fair Value near US$118 per share based on expectations for margin progress and EPS potential. Another might sit closer to a more cautious Narrative around US$90, reflecting concerns about integration challenges and competition. Comparing each Fair Value to the live share price can help you decide whether the stock looks closer to fully valued or offering a margin of safety under your own assumptions.

Do you think there's more to the story for Globus Medical? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.